title: In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens.
abstract: OBJECTIVE
  We compared different immunoglobulin preparations containing IgG (Intraglobin/Intratect) or a mixture of IgG, IgA, and IgM (Pentaglobin) to assess the opsonic and protective efficacy of human immunoglobulin preparations against multiresistent nosocomial pathogens.
  
  
  METHODS
  Clinical isolates of E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis, Enterococcus faecium, and Staphylococcus aureus were tested by opsonophagocytic assay using immunologobulin preparations at dilutions usually obtained in patients. The target antigens of opsonic antibodies were characterized by opsonophagocytic inhibition assays, and the protective efficacy in vivo was tested in a mouse bacteremia model as previously described.
  
  
  RESULTS
  All strains were killed to at least 50% by Pentaglobin. One P. aeruginosa strain was not efficiently killed by Intraglobin (23%) but the other strains were killed by Intraglobin to a similar degree compared to Pentaglobin. Opsonic IgG antibodies against E. faecalis were directed against LTA, while opsonic antibodies in Pentaglobin were primarily directed against other cell wall carbohydrates. In a mouse bacteremia model, Pentaglobin was more protective than Intratect against Staphylococcus aureus, while Intratect reduced colony counts better than normal rabbit serum or saline.
  
  
  CONCLUSIONS
  All tested human immunoglobulin preparations contain opsonic and protective antibodies against targets present on multiresistant Gram-positive and Gram-negative bacteria. Enrichment of these preparations with IgM increases the protective efficacy against some strains, probably due to antibodies directed against cell wall carbohydrates.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, University Hospital Freiburg, Freiburg im Breisgau, Germany.
authors.forename: F S
authors.initials: FS
authors.lastname: Rossmann
authors.forename: A
authors.initials: A
authors.lastname: Kropec
authors.forename: D
authors.initials: D
authors.lastname: Laverde
authors.forename: F R
authors.initials: FR
authors.lastname: Saaverda
authors.forename: D
authors.initials: D
authors.lastname: Wobser
authors.forename: J
authors.initials: J
authors.lastname: Huebner
mesh_terms: D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D003428:Cross Infection; D004195:Disease Models, Animal; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000494:pharmacology / Q000627:therapeutic use; D007075:Immunoglobulin M / Q000494:pharmacology / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D010587:Phagocytosis; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology
chemical_list: D007070:Immunoglobulin A; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; C060166:pentaglobulin